FDA inspection

Donald Rapini, MD/Clin Inv: FDA inspection ending Oct 29, 1999

FDA inspection 12612 · No Action Indicated (NAI) · Lubbock, TX

Key facts

Inspection ID	12612
Firm	Donald Rapini, MD/Clin Inv
FEI number	3002923713
Address	3601 4th St, Dept Of Dermatology, Texas Tech Univ Health Sciences
City	Lubbock
State	TX
ZIP	79430-0001
Fiscal year	2000
Inspection end date	Oct 29, 1999
Classification	No Action Indicated (NAI)
Project area	Bio-Research Monit: Human Drugs\|Bio-Research Monit: Human Drugs\|Bio-Research Monit: Human Drugs\|Bio-Research Monit: Human Drugs\|Bio-Research Monit: Human Drugs\|Bio-Research Monit: Human Drugs\|Bio-Research Monit: Human Drugs\|Bio-Research Monit: Human Drugs\|Bio-Research Monit: Human Drugs\|Bio-Research Monit: Human Drugs\|Bio-Research Monit: Human Drugs\|Bio-Research Monit: Human Drugs\|Bio-Research Monit: Human Drugs\|Bio-Research Monit: Human Drugs\|Bio-Research Monit: Human Drugs\|Bio-Research Monit: Human Drugs\|Bio-Research Monit: Human Drugs\|Bio-Research Monit: Human Drugs\|Bio-Research Monit: Human Drugs\|Bio-Research Monit: Human Drugs\|Bio-Research Monit: Human Drugs\|Bio-Research Monit: Human Drugs\|Bio-Research Monit: Human Drugs\|Bio-Research Monit: Human Drugs\|Bio-Research Monit: Human Drugs\|Bio-Research Monit: Human Drugs\|Bio-Research Monit: Human Drugs\|Bio-Research Monit: Human Drugs\|Bio-Research Monit: Human Drugs\|Bio-Research Monit: Human Drugs\|Bio-Research Monit: Human Drugs\|Bio-Research Monit: Human Drugs\|Bio-Research Monit: Human Drugs\|Bio-Research Monit: Human Drugs\|Bio-Research Monit: Human Drugs\|Bio-Research Monit: Human Drugs\|Bio-Research Monit: Human Drugs\|Bio-Research Monit: Human Drugs\|Bio-Research Monit: Human Drugs\|Bio-Research Monit: Human Drugs\|Bio-Research Monit: Human Drugs\|Bio-Research Monit: Human Drugs\|Bio-Research Monit: Human Drugs\|Bio-Research Monit: Human Drugs\|Bio-Research Monit: Human Drugs\|Bio-Research Monit: Human Drugs\|Bio-Research Monit: Human Drugs\|Bio-Research Monit: Human Drugs\|Bio-Research Monit: Human Drugs\|Bio-Research Monit: Human Drugs\|Bio-Research Monit: Human Drugs\|Bio-Research Monit: Human Drugs\|Bio-Research Monit: Human Drugs\|Bio-Research Monit: Human Drugs\|Bio-Research Monit: Human Drugs\|Bio-Research Monit: Human Drugs\|Bio-Research Monit: Human Drugs\|Bio-Research Monit: Human Drugs\|Bio-Research Monit: Human Drugs\|Bio-Research Monit: Human Drugs\|Bio-Research Monit: Human Drugs\|Bio-Research Monit: Human Drugs\|Bio-Research Monit: Human Drugs\|Bio-Research Monit: Human Drugs\|Bio-Research Monit: Human Drugs\|Bio-Research Monit: Human Drugs\|Bio-Research Monit: Human Drugs\|Bio-Research Monit: Human Drugs\|Bio-Research Monit: Human Drugs\|Bio-Research Monit: Human Drugs\|Bio-Research Monit: Human Drugs\|Drug Quality Assurance\|Drug Quality Assurance\|Drug Quality Assurance\|Drug Quality Assurance\|Drug Quality Assurance\|Drug Quality Assurance\|Drug Quality Assurance\|Drug Quality Assurance\|Drug Quality Assurance\|Drug Quality Assurance\|Drug Quality Assurance\|Drug Quality Assurance\|Drug Quality Assurance\|Drug Quality Assurance\|Drug Quality Assurance\|Drug Quality Assurance\|Drug Quality Assurance\|Drug Quality Assurance\|Drug Quality Assurance\|Drug Quality Assurance\|Drug Quality Assurance\|Drug Quality Assurance\|Drug Quality Assurance\|Drug Quality Assurance\|Drug Quality Assurance\|Drug Quality Assurance\|Drug Quality Assurance\|Drug Quality Assurance\|Drug Quality Assurance\|Drug Quality Assurance\|Drug Quality Assurance\|Drug Quality Assurance\|Drug Quality Assurance\|Drug Quality Assurance\|Drug Quality Assurance\|Drug Quality Assurance\|Drug Quality Assurance\|Drug Quality Assurance\|Drug Quality Assurance\|Drug Quality Assurance\|Drug Quality Assurance\|Drug Quality Assurance\|Drug Quality Assurance\|Drug Quality Assurance\|Drug Quality Assurance\|Drug Quality Assurance\|Drug Quality Assurance\|Drug Quality Assurance\|Drug Quality Assurance\|Drug Quality Assurance\|Drug Quality Assurance\|Drug Quality Assurance\|Drug Quality Assurance\|Drug Quality Assurance\|Drug Quality Assurance\|Drug Quality Assurance\|Drug Quality Assurance\|Drug Quality Assurance\|Drug Quality Assurance\|Drug Quality Assurance\|Drug Quality Assurance\|Drug Quality Assurance\|Drug Quality Assurance\|Drug Quality Assurance\|Drug Quality Assurance\|Drug Quality Assurance\|Drug Quality Assurance\|Drug Quality Assurance\|Drug Quality Assurance\|Drug Quality Assurance\|Drug Quality Assurance
Product type	Drugs

At a glance

None Citations
None Posted citations
No Warning letter followed
Yes Form FDA 483 issued
No Establishment inspection report (EIR) exists
1–9 Inspections at this FEI

Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.

About FDA inspections

FDA inspections are classified as No Action Indicated (NAI), Voluntary Action Indicated (VAI) or Official Action Indicated (OAI). Inspections of individual clinical investigators are not published here.

Source: U.S. Food and Drug Administration (FDA), inspection classification data

Browse all FDA inspections